Designed for the qualitative and semi-quantitative detection of cannabinoids (THC) in human urine, the DRI® Cannabinoid Assay ensures reliable toxicology screening.
Compatible with clinical chemistry analyzers that can maintain constant temperature, pipette samples, mix reagents, measure enzymatic rates at 340 nm, and accurately time reactions.
Provides excellent correlation with GC/MS, making it a trusted choice for accurate THC detection in medical and laboratory settings.
